Form 4: Y-mAbs Therapeutics Director Ashu Tyagi Boosts Equity Stake with Significant RSU and Stock Option Grants

Y-mAbs Therapeutics, Inc. Director Ashu Tyagi has increased beneficial ownership through the acquisition of 25,080 Restricted Stock Units and 33,450 employee stock options, aligning interests with shareholders.

Summary

• Ashu Tyagi, a Director of Y-mAbs Therapeutics, Inc. (YMAB), acquired 25,080 shares of common stock in the form of Restricted Stock Units (RSUs) on June 30, 2025.
• These RSUs were granted pursuant to the Issuer's 2018 Equity Incentive Plan and vest in full on the earlier of June 30, 2026, or the date immediately preceding the 2026 annual meeting of stockholders, subject to continued service.
• Following this transaction, Ashu Tyagi beneficially owns a total of 30,905 shares of common stock.
• Additionally, Ashu Tyagi was granted 33,450 employee stock options on June 30, 2025, with an exercise price of $4.51 per share.
• These stock options, also granted under the 2018 Equity Incentive Plan, vest in equal monthly installments until June 30, 2026, subject to continued service, and are exercisable immediately upon vesting.
• The stock options have an expiration date of June 30, 2035.
• After this transaction, Ashu Tyagi beneficially owns 33,450 derivative securities in the form of employee stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their equity stake in the company, which typically signals confidence and aligns management interests with shareholders.

Positives

• The acquisition of 25,080 Restricted Stock Units (RSUs) and 33,450 stock options by Director Ashu Tyagi significantly increases his equity stake in Y-mAbs Therapeutics, Inc.
• This grant aligns the director's financial interests more closely with those of the company's shareholders, signaling confidence in the company's future performance.
• The equity incentive plan encourages long-term commitment and performance from key personnel, as vesting is contingent on continued service.

Future Outlook

The document does not provide a future outlook or guidance for the company's financial performance or strategic direction.

Industry Context

This filing is a standard disclosure of an insider equity transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The increased equity ownership by a director can be seen as a positive sign of alignment between management and shareholder interests, potentially boosting investor confidence.

Next Steps

• Vesting of 25,080 Restricted Stock Units on the earlier of June 30, 2026, or the date immediately preceding the 2026 annual meeting of stockholders.
• Continued monthly vesting of 33,450 employee stock options until June 30, 2026.

Key Dates

Recommendation

Keywords

Y-mAbs Therapeutics, YMAB, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Equity Incentive Plan